clinical trial · NCT03621280
Open-label Treatment in Cushing's Syndrome
Cortendo AB·phase3·completed·n = 51
Cushing SyndromeCushing DiseaseLevoketoconazole
brief summary
This is a long-term, open-label extension study of levoketoconazole in participants with endogenous Cushing's Syndrome.
started
Jan 7, 2019
primary completion
Dec 31, 2022
completion
Dec 31, 2022
last updated
Jun 19, 2025
detailed description
This is a long-term, open-label extension (OLE) study of levoketoconazole in participants with endogenous Cushing's Syndrome (CS) who have completed one or both parent studies or otherwise potentially qualify for this study, as defined in the eligibility criteria.
official title
An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol